Active substances set

Search phrase: ipilimumab

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Colon and rectum cancer

Ipilimumab	Ipilimumab in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high colorectal cancer in the following settings: - first-line treatment of unresectable or metastatic colorectal cancer; - treatment of metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy.	NO REIMBURSEMENT ESMO

Liver cancer

Ipilimumab	Hepatocellular carcinoma (HCC) Ipilimumab in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma.	NO REIMBURSEMENT ESMO

Tracheal, bronchus, and lung cancer

Ipilimumab	Ipilimumab in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.	REIMBURSEMENT WITH RESTRICTIONS ESMO

Kidney cancer

Ipilimumab	Ipilimumab in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma.	FULL REIMBURSEMENT ESMO